9. January 2015

FDA Approves Roche's Blood Screening Assay for Simultaneous Detection and Identification of Three Major Viral Targets

Roche announced today that the FDA has approved the cobas® TaqScreen MPX Test, v2.0 for use in the detection and identification of HIV, HCV, and HBV in donations of human whole blood and blood components including source plasma.


Learn about liquid biopsy testing for EGFR
What's New

20. June 2016

Roche announces availability of the LightMix Modular Zika Virus Assay (CE) in markets accepting the CE mark

Roche and TIB MOLBIOL, GmbH, announced the availability of the LightMix Modular Zika Virus Assay (CE) in markets accepting the CE mark for patients with signs and symptoms of Zika virus infection living in affected areas where the Zika virus is known to be present.


1. June 2016

FDA Grants First Liquid Biopsy Approval to the Roche cobas® EGFR Mutation Test v2

Test can be used with either plasma or tumor tissue, as a companion diagnostic for non-small cell lung cancer therapy.


25. May 2016

Roche announces the first FDA-approved CMV test for use in hematopoietic stem cell transplant recipients

New test standardizes CMV testing for both solid organ and hematopoietic stem cell transplant recipients.


30. March 2016

Roche to initiate testing for Zika virus at U.S. Blood Centres under FDA Investigational New Drug Application protocol

New cobas® Zika test will screen blood samples on the cobas® 6800/8800 Systems.


 Diagnostic and Blood Screening Tests


Roche Molecular Diagnostics (RMD) offers a uniquely broad range of diagnostic and blood screening assays based on the company's Nobel prize-winning PCR technologies.


RMD's tests and automated platforms are focused in the areas of virology, blood screening, HPV, genomics and oncology, microbiology and sexually transmitted infections. > more


Contact your local sales representative for detailed information, questions and ordering.



 Browse Our Products

 Related Links